ADAMTS13 and COVID-19: A study of 88 PCR-proven COVID-19 patients demonstrated that COVID-19 non-survivors had significantly lower levels of ADAMTS-13 activity (32.2 iu/dL vs. 50.6 iu/dL, p = 0.035) and higher levels of vWF (395.5 iu/dL vs. 295.5 iu/dL, p = 0.033) when compared to patients who survived [45].